Efficacy and safety of eslicarbazepine acetate versus controlled-release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double-blind, randomized, parallel-group, multicenter study

Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial

(2017) Michel Baulac et al.   LANCET NEUROLOGY

Nonadherence to antiepileptic drugs in Germany

(2016) Stephanie Gollwitzer et al.   NEUROLOGY

Conversion to eslicarbazepine acetate monotherapy

(2016) Michael R. Sperling et al.   NEUROLOGY

Assessment of the efficacy and safety of eslicarbazepine acetate in acute mania and prevention of recurrence: Experience from multicentre, double-blind, randomised phase II clinical studies in patients with bipolar disorder I

(2015) Heinz Grunze et al.   JOURNAL OF AFFECTIVE DISORDERS

Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial

(2014) Michael R. Sperling et al.   EPILEPSIA

ILAE Official Report: A practical clinical definition of epilepsy

(2014) Robert S. Fisher et al.   EPILEPSIA

Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes

(2013) Tracy Glauser et al.   EPILEPSIA

Ideal characteristics of an antiepileptic drug: how do these impact treatment decisions for individual patients?

(2012) E. Trinka   ACTA NEUROLOGICA SCANDINAVICA

Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: Integrated analysis of pooled data from double-blind phase III clinical studies

(2012) António Gil-Nagel et al.   EPILEPSIA

KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy

(2012) Eugen Trinka et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial

(2012) Michel Baulac et al.   LANCET NEUROLOGY

Efficacy and safety of pregabalin versus lamotrigine in patients with newly diagnosed partial seizures: a phase 3, double-blind, randomised, parallel-group trial

(2011) Patrick Kwan et al.   LANCET NEUROLOGY

The pharmacological treatment of epilepsy in adults

(2011) Emilio Perucca et al.   LANCET NEUROLOGY

Estimating adjusted NNTs in randomised controlled trials with binary outcomes: A simulation study

(2010) Ralf Bender et al.   Contemporary Clinical Trials

Long-term efficacy and safety of eslicarbazepine acetate: Results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy

(2010) Peter Halász et al.   EPILEPSIA

Measuring outcomes of treatment with antiepileptic drugs in clinical trials

(2010) Elinor Ben-Menachem et al.   EPILEPSY & BEHAVIOR

Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy

(2010) E. Ben-Menachem et al.   EPILEPSY RESEARCH

Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures

(2009) A. Gil-Nagel et al.   ACTA NEUROLOGICA SCANDINAVICA

Antiepileptic Drug Monotherapy: The Initial Approach in Epilepsy Management

(2009) Erik St. Louis et al.   Current Neuropharmacology

Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: A randomized, double-blind, placebo-controlled, parallel-group phase III study

(2009) Christian Elger et al.   EPILEPSIA

Absolute risk reductions, relative risks, relative risk reductions, and numbers needed to treat can be obtained from a logistic regression model

(2009) Peter C. Austin   JOURNAL OF CLINICAL EPIDEMIOLOGY

Impact of nonadherence to antiepileptic drugs on health care utilization and costs: Findings from the RANSOM study

(2008) R. Edward Faught et al.   EPILEPSIA